Real world validation of an AI-based CT hemorrhage detection tool.

Introduction: Intracranial hemorrhage (ICH) is a potentially life-threatening medical event that requires expedited diagnosis with computed tomography (CT). Automated medical imaging triaging tools can rapidly bring scans containing critical abnormalities, such as ICH, to the attention of radiologists and clinicians. Here, we retrospectively investigated the real-world performance of VeriScout ^™ , an artificial intelligence-based CT hemorrhage detection and triage tool.
Methods: Ground truth for the presence or absence of ICH was iteratively determined by expert consensus in an unselected dataset of 527 consecutively acquired non-contrast head CT scans, which were sub-grouped according to the presence of artefact, post-operative features and referral source. The performance of VeriScout ^™ was compared with the ground truths for all groups.
Results: VeriScout ^™ detected hemorrhage with a sensitivity of 0.92 (CI 0.84-0.96) and a specificity of 0.96 (CI 0.94-0.98) in the global dataset, exceeding the sensitivity of general radiologists (0.88) with only a minor relative decrement in specificity (0.98). Crucially, the AI tool detected 13/14 cases of subarachnoid hemorrhage, a potentially fatal condition that is often missed in emergency department settings. There was no decrement in the performance of VeriScout ^™ in scans containing artefact or postoperative change. Using an integrated informatics platform, VeriScout ^™ was deployed into the existing radiology workflow. Detected hemorrhage cases were flagged in the hospital radiology information system (RIS) and relevant, annotated, preview images made available in the picture archiving and communications system (PACS) within 10 min.
Conclusion: AI-based radiology worklist prioritization for critical abnormalities, such as ICH, may enhance patient care without adding to radiologist or clinician burden.
Competing Interests: DW, CS and CW are part-time employees at the Sydney Neuroimaging Analysis Centre (SNAC). MB has received institutional support for research, speaking and/or participation in advisory boards for Biogen, Merck, Novartis, Roche, and Sanofi Genzyme, and is a research consultant to RxPx and research director for the SNAC. YB and TD are consulting radiologists for SNAC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Wang, Jin, Shieh, Ng, Pham, Dugal, Barnett, Winoto, Wang and Barnett.)